Mirae Asset Global Etfs Holdings Ltd. Nektar Therapeutics Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $43.9 Billion
- Q4 2024
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Nektar Therapeutics stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 102,362 shares of NKTR stock, worth $90,078. This represents 0.0% of its overall portfolio holdings.
Number of Shares
102,362
Previous 97,954
4.5%
Holding current value
$90,078
Previous $127,000
25.2%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding NKTR
# of Institutions
153Shares Held
131MCall Options Held
92.7KPut Options Held
4.9K-
Black Rock Inc. New York, NY15.2MShares$13.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.3MShares$10.8 Million0.0% of portfolio
-
Samlyn Capital, LLC New York, NY9.67MShares$8.51 Million0.14% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT7.81MShares$6.87 Million0.37% of portfolio
-
Acadian Asset Management LLC Boston, MA7.2MShares$6.34 Million0.02% of portfolio
About NEKTAR THERAPEUTICS
- Ticker NKTR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 187,404,992
- Market Cap $165M
- Description
- Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...